ACLY and neoplasm: Tumor burden was remarkably greater in the KR mutant group compared to WT, irrespective of 5‐FU treatment (Figure 2h–j), indicating that ACLY‐K978 drives CRC chemoresistance in a deacetylation‐dependent manner.